Suzan Imren

3.2k total citations
43 papers, 1.5k citations indexed

About

Suzan Imren is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Suzan Imren has authored 43 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hematology, 20 papers in Molecular Biology and 12 papers in Genetics. Recurrent topics in Suzan Imren's work include Acute Myeloid Leukemia Research (12 papers), Hematopoietic Stem Cell Transplantation (12 papers) and CRISPR and Genetic Engineering (8 papers). Suzan Imren is often cited by papers focused on Acute Myeloid Leukemia Research (12 papers), Hematopoietic Stem Cell Transplantation (12 papers) and CRISPR and Genetic Engineering (8 papers). Suzan Imren collaborates with scholars based in United States, Canada and Germany. Suzan Imren's co-authors include Yves A. DeClerck, R. Keith Humphries, Connie J. Eaves, Laurence Blavier, Philippe Leboulch, Ronald L. Nagel, Mary E. Fabry, Karen A. Westerman, Robert Pawliuk and Donald B. Kohn and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Suzan Imren

37 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Suzan Imren United States 20 769 429 420 384 319 43 1.5k
Anna Kalota United States 17 901 1.2× 460 1.1× 339 0.8× 219 0.6× 158 0.5× 39 1.5k
Rebecca G. Bagley United States 23 952 1.2× 91 0.2× 474 1.1× 264 0.7× 230 0.7× 51 1.6k
François Mercier Canada 16 1.1k 1.4× 642 1.5× 311 0.7× 428 1.1× 142 0.4× 51 2.1k
Keichiro Mihara Japan 21 914 1.2× 491 1.1× 1.2k 2.8× 252 0.7× 340 1.1× 70 2.4k
Michael Rosu‐Myles Canada 23 704 0.9× 319 0.7× 322 0.8× 242 0.6× 51 0.2× 48 1.4k
Nuria Mencia-Trinchant United States 14 579 0.8× 468 1.1× 222 0.5× 288 0.8× 89 0.3× 27 1.3k
Guillermo Güenechea Spain 20 1.3k 1.7× 438 1.0× 340 0.8× 90 0.2× 586 1.8× 42 1.9k
Florence Smadja‐Joffe France 23 1.3k 1.7× 907 2.1× 827 2.0× 251 0.7× 315 1.0× 51 2.6k
Brandon Harder United States 14 372 0.5× 246 0.6× 332 0.8× 92 0.2× 180 0.6× 19 1.4k
Marta Baiocchi Italy 19 794 1.0× 151 0.4× 459 1.1× 208 0.5× 83 0.3× 38 1.5k

Countries citing papers authored by Suzan Imren

Since Specialization
Citations

This map shows the geographic impact of Suzan Imren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suzan Imren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suzan Imren more than expected).

Fields of papers citing papers by Suzan Imren

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suzan Imren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suzan Imren. The network helps show where Suzan Imren may publish in the future.

Co-authorship network of co-authors of Suzan Imren

This figure shows the co-authorship network connecting the top 25 collaborators of Suzan Imren. A scholar is included among the top collaborators of Suzan Imren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suzan Imren. Suzan Imren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Frangoul, Haydar, Franco Locatelli, Michael J. Eckrich, et al.. (2025). Impact of Different Definitions of Vaso-Occlusion on Efficacy Assessments in Sickle Cell Disease Clinical Trials. Advances in Therapy. 42(5). 2490–2499.
3.
4.
Sharma, Akshay, Haydar Frangoul, Franco Locatelli, et al.. (2024). Health-Related Quality-of-Life Improvements after Exagamglogene Autotemcel in Patients with Severe Sickle Cell Disease. Blood. 144(Supplement 1). 7453–7453.
5.
6.
Sharma, Akshay, Haydar Frangoul, Markus Y. Mapara, et al.. (2023). Improvements in Health-Related Quality of Life after Exagamglogene Autotemcel in Patients with Severe Sickle Cell Disease. Blood. 142(Supplement 1). 4999–4999. 2 indexed citations
7.
Locatelli, Franco, et al.. (2023). PB2508: COMPARING DEFINITIONS OF EPISODES OF VASO-OCCLUSION AS ENDPOINTS IN CLINICAL STUDIES OF SICKLE CELL DISEASE. HemaSphere. 7(S3). e6522522–e6522522.
8.
Kloos, Arnold, Razif Gabdoulline, Nidhi Jyotsana, et al.. (2020). Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia. Leukemia. 34(11). 2951–2963. 9 indexed citations
9.
Ngom, Mor, Suzan Imren, Tobias Maetzig, et al.. (2018). UM171 Enhances Lentiviral Gene Transfer and Recovery of Primitive Human Hematopoietic Cells. Molecular Therapy — Methods & Clinical Development. 10. 156–164. 22 indexed citations
10.
Pabst, Caroline, Anne Bergeron, Vincent‐Philippe Lavallée, et al.. (2016). GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo. Blood. 127(16). 2018–2027. 115 indexed citations
11.
Gasparetto, Maura, Sanja Sekulovic, Suzan Imren, et al.. (2012). Varying levels of aldehyde dehydrogenase activity in adult murine marrow hematopoietic stem cells are associated with engraftment and cell cycle status. Experimental Hematology. 40(10). 857–866.e5. 13 indexed citations
12.
Imren, Suzan, et al.. (2010). Insights into leukemia-initiating cell frequency and self-renewal from a novel canine model of leukemia. Experimental Hematology. 39(1). 124–132. 1 indexed citations
13.
Xiang, Ping, Bob Argiropoulos, A. MAUREEN ROUHI, et al.. (2010). Identification of E74-like factor 1 (ELF1) as a transcriptional regulator of the Hox cofactor MEIS1. Experimental Hematology. 38(9). 798–808.e2. 20 indexed citations
14.
Christ, Oliver, Suzan Imren, Karen Leung, et al.. (2007). Improved purification of hematopoietic stem cells based on their elevated aldehyde dehydrogenase activity. Haematologica. 92(9). 1165–1172. 65 indexed citations
15.
Imren, Suzan, Mary E. Fabry, Karen A. Westerman, et al.. (2004). High-level β-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells. Journal of Clinical Investigation. 114(7). 953–962. 94 indexed citations
16.
Abramovich, Carolina, Weifeng Shen, Nicolas Pineault, et al.. (2000). Functional Cloning and Characterization of a Novel Nonhomeodomain Protein That Inhibits the Binding of PBX1-HOX Complexes to DNA. Journal of Biological Chemistry. 275(34). 26172–26177. 54 indexed citations
17.
Luo, Michelle P., Brigitte N. Gomperts, Suzan Imren, et al.. (1997). Establishment of Long-Termin VitroCultures of Human Ovarian Cystadenomas and LMP Tumors and Examination of Their Spectrum of Expression of Matrix-Degrading Proteinases. Gynecologic Oncology. 67(3). 277–284. 21 indexed citations
18.
DeClerck, Yves A., Suzan Imren, Anthony M.P. Montgomery, et al.. (1997). Proteases and Protease Inhibitors in Tumor Progression. Advances in experimental medicine and biology. 425. 89–97. 99 indexed citations
19.
Imren, Suzan, Donald B. Kohn, Hiroyuki Shimada, Laurence Blavier, & Yves A. DeClerck. (1996). Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion.. PubMed. 56(13). 2891–5. 115 indexed citations
20.
DeClerck, Yves A. & Suzan Imren. (1994). Protease inhibitors: Role and potential therapeutic use in human cancer. European Journal of Cancer. 30(14). 2170–2180. 108 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anna Kalota Breakdown of academic impact, for papers by Rebecca G. Bagley Breakdown of academic impact, for papers by François Mercier Breakdown of academic impact, for papers by Keichiro Mihara Breakdown of academic impact, for papers by Michael Rosu‐Myles Breakdown of academic impact, for papers by Nuria Mencia-Trinchant Breakdown of academic impact, for papers by Guillermo Güenechea Breakdown of academic impact, for papers by Florence Smadja‐Joffe Breakdown of academic impact, for papers by Brandon Harder Breakdown of academic impact, for papers by Marta Baiocchi
Rankless by CCL
2026